Mabpharm Limited (HKG:2181)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
0.4550
+0.0150 (3.41%)
Apr 17, 2026, 3:26 PM HKT
Market Cap1.81B -8.3%
Revenue (ttm)718.98M +150.2%
Net Income63.58M
EPS0.01
Shares Out4.12B
PE Ratio39.54
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume88,000
Average Volume2,242,950
Open0.4450
Previous Close0.4400
Day's Range0.4450 - 0.4550
52-Week Range0.4000 - 0.8800
Beta0.68
RSI44.21
Earnings DateMar 26, 2026

About Mabpharm

Mabpharm Limited, a biopharmaceutical company, engages in research, development, production, and commercialization of drugs and biosimilar for cancers and autoimmune diseases in the People’s Republic of China. The company offers CMAB007, a recombinant humanized anti-immunoglobulin E monoclonal antibody for treatment of asthma patients; CMAB009, a recombinant anti-EGFR chimeric monoclonal antibody for the first-line treatment of metastatic colorectal cancer; and CMAB008, a recombinant anti-TNF-alpha chimeric monoclonal antibody for the treatment... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Employees 389
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2181
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements